

25 October 2022

ASX Announcement

## Nasodine Patent Granted in Singapore

---

- **Nasodine® Nasal Spray core patent now granted in 27 countries**

**Firebrick Pharma Limited** (ASX:FRE) (**Company** or **Firebrick**) is pleased to announce that its patent covering Nasodine® Nasal Spray (“Nasodine”) as a treatment and preventative for the common cold has been granted in Singapore.

This brings the number of countries where Firebrick’s core patent has been granted to 27, including:

Australia	Great Britain	Portugal
Austria	Greece	Sweden
Belgium	Hong Kong	Turkey
Switzerland	Hungary	Malaysia
Germany	Ireland	New Zealand
Denmark	Italy	Philippines
Spain	Netherlands	Singapore
Finland	Norway	South Africa
France	Poland	United States

The patent is still pending in Canada and Japan. The pending application in China has now been withdrawn, following a recent assessment of the likelihood and costs of gaining any commercially-useful protection in that market.

The core Nasodine patent, which expires in most countries in 2035, is titled: “*Treatment and prevention of the common cold using povidone-iodine*,” and protects the intranasal use of povidone-iodine (in any form) for the treatment or prevention of the common cold.

Granted claims include treating and preventing colds, reducing the viral load of common cold viruses, prevention of secondary complications of colds, and reducing the risk of serious complications in at-risk populations.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman, Firebrick Pharma Limited.

- ENDS -

**About Firebrick (ASX:FRE)**

Firebrick is a pharmaceutical company founded in 2012 to develop and commercialise a nasal spray treatment for the common cold based around the potential of povidone-iodine as a broad-spectrum antimicrobial agent. The Company subsequently developed Nasodine® Nasal Spray (“Nasodine”) and owns numerous granted and pending patents. Firebrick is currently undertaking two significant clinical trials: A Phase 2 trial of Nasodine in COVID-19 and a Phase 3 trial for Nasodine, to confirm its efficacy as a treatment for the common cold and support international approvals.

**Media enquiries:**

Heidi Cuthbert  
+61 411 272 366  
[heidi.cuthbert@multiplier.com.au](mailto:heidi.cuthbert@multiplier.com.au)

**Investor enquiries:**

[Investors@firebrickpharma.com](mailto:Investors@firebrickpharma.com)